UNSPSC 51322205: Rosuvastatin calcium

This classification denotes a hmg-coa reductase inhibitor with the molecular formula 2C22H27FN3O6S.CA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83MVU38M7Q. European Medicines Agency schedules rosuvastatin calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20721. The term rosuvastatin calcium is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule rosuvastatin calcium under HS 29350090 and SITC 51580.

UNSPSC 51322205 Rosuvastatin calcium is a Commodity code covering pharmaceutical supply to state and local health agencies, emergency services, and public health programs. State and local governments procure this statin and related medications through direct procurement from manufacturers and wholesalers to stock emergency response units, public health clinics, and institutional healthcare facilities. The issuing bodies span city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances coordinating procurement for dozens of participating jurisdictions. Solicitations under this code include both direct goods buys for immediate operational needs and larger framework agreements establishing pricing and supply relationships across multiple states and vendor channels.

Recent activity shows geographic concentration in Florida and Texas, with multistate cooperative structures serving the upper Midwest and Pacific Northwest. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (Bid 26P00188) via IFB with a due date of April 8, 2026, for Tampa Fire Rescue, requesting four medication line items with nine-month minimum expiration and a 120-day award window; the estimated contract value was $40,000 with a 5 percent Small Local Business Enterprise bid discount available. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) with a March 26, 2026 response date for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, requiring manufacturer pricing through three authorized wholesalers with a July 1, 2026 effective date and performance penalties of $200 to $1,500 per violation. Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to establish direct contracting relationships outside traditional pharmacy benefit managers and wholesalers.